Hardiman: Role of research in developing anthrax countermeasures 291 8. Hudson MJ, Beyer W, Bohm R, Fasanella A, Garofolo G, Golinski R, et al. Bacillus an- thracis: balancing innocent research with dual-use potential. Int J Med Microbiol. 2008;298(5-6):345-64. 9. Schwartz M. Dr. Jekyll and Mr. Hyde: a short history of anthrax. Mol Aspects Med. 2009;30(6):347-55. 10. Ezzell JW, Ivins BE, Leppla SH. Immuno- electrophoretic analysis, toxicity, and kinet- ics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun. 1984;45(3):761-7. 11. Blaustein RO, Koehler TM, Collier RJ, Finkelstein A. Anthrax toxin: channel-form- ing activity of protective antigen in planar phospholipid bilayers. Proc Natl Acad Sci USA. 1989;86(7):2209-13. 12. Leppla SH. Anthrax toxin edema factor: a bac- terial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA. 1982;79(10):3162-6. 13. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 1998;280(5364):734-7. 14. Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and in- duces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun. 1998;248(3):706-11. 15. Smith H, Keppie J. Observations on experi- mental anthrax; demonstration of a specific lethal factor produced in vivo by Bacillus an- thracis. Nature. 1954;173(4410):869-70. 16. Uchida I, Hashimoto K, Terakado N. Viru- lence and immunogenicity in experimental animals of Bacillus anthracis strains har- bouring or lacking 110 MDa and 60 MDa plasmids. J Gen Microbiol. 1986;132(2):557- 9. 17. Project BioShield: Authorities, Appropria- tions, and Issues for Congress [Internet]. [cited 2012 Mar 19]. Available from: http://fpc.state.gov/documents/organiza- tion/145580.pdf. 18. Stanley JL, Smith H. The three factors of an- thrax toxin: their immunogenicity and lack of demonstrable enzymic activity. J Gen Micro- biol. 1963;31:329-37. 19. Fish DC, Mahlandt BG, Dobbs JP, Lincoln RE. Purification and properties of in vitro- produced anthrax toxin components. J Bac- teriol. 1968;95(3):907-18. 20. Keitel WA. Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine. Expert Rev Vaccines. 2006;5(4):417-30. 21. Milne JC, Furlong D, Hanna PC, Wall JS, Collier RJ. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J Biol Chem. 1994;269(32):20607-12. 22. Kintzer AF, Thoren KL, Sterling HJ, Dong KC, Feld GK, Tang II, et al. The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol. 2009;392(3):614-29. 23. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. 1986;261(16):7123-6. 24. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. Crystal structure of the anthrax toxin protective antigen. Nature. 1997;385(6619):833-8. 25. Krantz BA, Melnyk RA, Zhang S, Juris SJ, Lacy DB, Wu Z, et al. A phenylalanine clamp catalyzes protein translocation through the an- thrax toxin pore. Science. 2005;309(5735):777- 81. 26. Sellman BR, Mourez M, Collier RJ. Domi- nant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science. 2001;292(5517):695-7. 27. Aulinger BA, Roehrl MH, Mekalanos JJ, Collier RJ, Wang JY. Combining anthrax vac- cine and therapy: a dominant-negative in- hibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun. 2005;73(6):3408-14. 28. Young JA, Collier RJ. Anthrax toxin: recep- tor binding, internalization, pore formation, and translocation. Annu Rev Biochem. 2007;76:243-65. 29. Soligenix, Inc. News and Events [Internet]. [cited 2012 Mar 19]. Available from: http://www.soligenix.com/news.aspx?ti- tleId=380. 30. Soligenix, Inc. orBec(R), oral BDP, LPM(TM) Leuprolide, RiVax(TM) ricin toxin vaccine [Internet]. [cited 2012 Mar 19]. Available from: http://www.soligenix.com/prod.shtml 31. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. Nature. 2001;414(6860):225-9. 32. Scobie HM, Rainey GJ, Bradley KA, Young JA. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA. 2003;100(9):5170-4. 33. Klimpel KR, Molloy SS, Thomas G, Leppla SH. Anthrax toxin protective antigen is acti- vated by a cell surface protease with the se- quence specificity and catalytic properties of furin. Proc Natl Acad Sci USA. 1992;89(21):10277-81. 34. Singh Y, Chaudhary VK, Leppla SH. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem.1989;264(32):19103-7. 35. Gordon VM, Leppla SH, Hewlett EL. In- hibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adeny-